Previous 10 | Next 10 |
Black Diamond Therapeutics press release ( NASDAQ: BDTX ): Q2 GAAP EPS of -$0.63 beats by $0.07 . Black Diamond ended the second quarter of 2022 with approximately $160.9 million in cash, cash equivalents, and investments compared to $209.8 million as of December 31, 2...
Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer Advanced MasterKey therapy pipeline with first patient dosed in Phase 1 global study of BDTX-1535, and continued IND-enabling studies of BDTX-4933 Cash, cash equivale...
CAMBRIDGE, Mass. and NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. E...
CAMBRIDGE, Mass. and NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. E...
- Dr. Yurasov brings over 25 years of experience in oncology drug development and regulatory expertise - CAMBRIDGE, Mass. and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery...
CAMBRIDGE, Mass. and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Ep...
- Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine - CAMBRIDGE, Mass. and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology med...
Black Diamond Therapeutics press release (NASDAQ:BDTX): Q1 GAAP EPS of -$0.70. The company has decided to discontinue the development of BDTX-189 and reduce its workforce by approximately 30% to extend its cash runway into the third quarter of 2024. Black Diamond ended the first quarter of 20...
Dosed first patient in Phase 1 Study of BDTX-1535 for the treatment of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC) including those with central nervous system (CNS) tumors; clinical update expected in 2023 Continued strategic focus on development of BD...
Black Diamond Therapeutics (NASDAQ:BDTX) on Monday said it would discontinue the development of its BDTX-189 product and reduce its workforce by about 30%. The company will focus on development of its BDTX-1535 and BDTX-4933 programs, along with other discovery efforts. BDTX-189 is a sma...
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
Black Diamond Therapeutics Inc. Website:
2024-07-31 09:00:12 ET Laura Prendergast from Raymond James issued a price target of $20.00 for BDTX on 2024-07-31 08:18:00. The adjusted price target was set to $20.00. At the time of the announcement, BDTX was trading at $5.91. The overall price target consensus is at ...
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...